Related Experiment Video
Updated: Jun 24, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Driving in the melanoma landscape
1The Wistar Institute, Philadelphia, PA 19104, USA. herlynm@wistar.org
Abstract:
The melanoma landscape is rapidly evolving. The melanoma oncologists have now the first successful targets for therapy that have a genetic base--albeit in rare forms of the malignancy. Once melanoma becomes part of the Cancer Genome Atlas consortium, a comprehensive map of genetic changes will be established to point the field to true drivers of the disease that will become new targets for therapy. The same abnormalities will also serve as biomarkers for diagnosis, prognosis and therapy follow-up. Melanomas as a group are heterogeneous as are tumor cells within one lesion. New strategies will move towards individualized therapies and combination therapies to target all cells within a tumor.
Insights
Advances in melanoma research reveal genetically targeted therapies for rare forms. Comprehensive genomic mapping will identify new treatment targets and biomarkers for diagnosis and prognosis, paving the way for personalized and combination therapies.
Area of Science:
- Oncology
- Genetics
- Cancer Research
Background:
- The field of melanoma treatment is rapidly advancing.
- Current targeted therapies exist for rare genetic forms of melanoma.
Purpose of the Study:
- To outline the evolving landscape of melanoma research and treatment.
- To highlight the potential of genomic data in identifying new therapeutic targets and biomarkers.
Main Methods:
- Integration of melanoma into the Cancer Genome Atlas (TCGA) consortium.
- Comprehensive genomic analysis to identify genetic drivers.
- Utilizing identified abnormalities as biomarkers.
Main Results:
- Establishment of a comprehensive map of genetic alterations in melanoma.
- Identification of potential new therapeutic targets based on genetic drivers.
- Validation of genetic abnormalities as biomarkers for diagnosis, prognosis, and treatment monitoring.
Conclusions:
- Genomic initiatives like TCGA are crucial for understanding melanoma drivers.
- Identified genetic abnormalities serve dual roles as therapeutic targets and biomarkers.
- Future melanoma treatment strategies will focus on individualized and combination therapies to address tumor heterogeneity.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Pigmentation
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
Cancer Prevention
Some...
Cancer Prevention
Some...
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

